Case-Based Tumor Board: Confronting Management Controversies in Renal Cell Carcinoma

Michael A. Brooks, MD; A. Edward Yen, MD; Richard E. Link, MD, PhD; and Wesley A. Mayer, MD, presented “Case-Based Tumor Board: Confronting Management Controversies in Renal Cell Carcinoma” during the 24th Annual Innovations in Urologic Practice on September 14, 2019 in Santa Fe, New Mexico.

How to cite: Brooks, Michael A., Yen, A. Edward, Link, Richard E., and Mayer, Wesley A. “Case-Based Tumor Board: Confronting Management Controversies in Renal Cell Carcinoma” September 14, 2019. Accessed Nov 2019. https://grandroundsinurology.com/case-based-tumor-board-confronting-management-controversies-in-renal-cell-carcinoma​/

Case-Based Tumor Board: Confronting Management Controversies in Renal Cell Carcinoma – Summary:

Michael A. Brooks, MD; A. Edward Yen, MD; Richard E. Link, MD, PhD; and Wesley A. Mayer, MD, an interdisciplinary panel of kidney cancer experts, present representative cases of renal cell carcinoma in order to discuss current management controversies. The session reviews data supporting management recommendations, surgical approaches for small renal masses, lymphadenectomy, adjuvant therapy, and cytoreductive nephrectomy and partial nephrectomy.

Abstract:

There will be an estimated 73,820 new cases of kidney cancer in the United States in 2019. The incidence of this disease has been increasing steadily over the past 4 decades. While the greatest increase in incidence has been in clinically localized disease, renal masses, in general, are a biologically heterogeneous group of tumors. Small renal masses can be either benign or malignant, with the latter ranging in behavior from indolent to aggressive. 

As such, the management of this disease process is just as varied as its presentation. Various strategies employed include active surveillance, nephron-sparing surgery, radical nephrectomy, and systemic therapy. Furthermore, there is a wide range of surgical and interdisciplinary options to treat this disease.

This session confronts current management controversies in renal cell carcinoma via a case-based, tumor board format. It will also expound on the data supporting management recommendations, particularly commenting on the 2017 American Urological Association Guideline for Renal Mass and Localized Renal Cancer.

The session will cover surgical approach considerations for the management of small renal masses, the current role of lymphadenectomy in the surgical management of kidney cancer, adjuvant therapy for kidney cancer, the shifting paradigm for cytoreductive nephrectomy, and the potential role of cytoreductive partial nephrectomy.

About the 24th Annual Innovations in Urologic Practice

Innovations in Urologic Practice (Innovations) is an annual, multi-day, CME-accredited conference devoted to innovative diagnostic and treatment strategies for and controversies related to some of the most common urologic problems in the current era. The topics covered include oncological management of the bladder, kidney, and prostate. The conference also emphasizes general urology topics in pelvic reconstruction and trauma, men’s health, and infections in the urology patient. Drs. Brooks, Yen, Link, and Mayer presented this lecture during the 24th Innovations in 2019. Please visit this page in order to register for future Innovations meetings.